30 Day Trial

NuVasive Reports Preliminary 4Q15 and 2015 Revenue

Share:

NuVasive announced preliminary unaudited 2015 sales of ~US $811MM, +8% from 2014, and 4Q15 revenue of ~$215MM. (Growth reflects constant currency.)

For 2016, the company announced full-year guidance of ~$870MM, +7% from 2015. This guidance suggests an increased take of market share in a strengthening U.S. and ex-U.S. spine market and excludes the planned acquisition of Ellipse Technologies. (For 2016, Ellipse's revenues are expected to be ~$60MM pro forma.)

Source: NuVasive, Inc.